Epoetin-induced autoimmune pure red cell aplasia.
Casadevall
Nicole
N
Hôpital Hôtel-Dieu, Paris, France.
D000918:Antibody Specificity; D001323:Autoantibodies / Q000276:immunology; D001324:Autoantigens / Q000276:immunology; D001327:Autoimmune Diseases / Q000139:chemically induced* / Q000188:drug therapy / Q000453:epidemiology / Q000276:immunology; D002626:Chemistry, Pharmaceutical; D004340:Drug Contamination; D000068817:Epoetin Alfa; D004921:Erythropoietin / Q000008:administration & dosage / Q000009:adverse effects* / Q000276:immunology / Q000627:therapeutic use; D005060:Europe / Q000453:epidemiology; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007279:Injections, Subcutaneous; D011379:Prognosis; D011994:Recombinant Proteins; D012010:Red-Cell Aplasia, Pure / Q000139:chemically induced* / Q000188:drug therapy / Q000453:epidemiology / Q000276:immunology; D012307:Risk Factors; D013012:Sorbitol / Q000009:adverse effects; D016896:Treatment Outcome
D001323:Autoantibodies; D001324:Autoantigens; D007166:Immunosuppressive Agents; D011994:Recombinant Proteins; C103998:epoetin beta; D004921:Erythropoietin; D013012:Sorbitol; D000068817:Epoetin Alfa